http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017201994-A9
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d88967fe5b3e3b4697d50be7cab31924 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate | 2016-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93242059650037d2a76eae5b9535ff80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fa4809944fd4cd79d00b6df7e39bb7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ec33817268554971bc527f4c7551bd9 |
| publicationDate | 2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017201994-A9 |
| titleOfInvention | Use of purified antrodia cinnamomea extract |
| abstract | A purified dehydroeburicoic acid extracted from an Antrodia cinnamomea and use thereof in anti-type 2 diabetic, anti-hypertriglyceridemic, and anti-hypercholesterolemic applications, and for lowering liver fat accumulation. The purified compound is a dehydroeburicoic acid (TT) extracted from an Antrodia cinnamomea mycelium. Measurements of increased expressions of a glucose transporter 4 (GLUT4) in skeletal muscle cell membrane, peroxisome proliferator-activated receptor α (PPARα) in liver, and phospho-AMP-activated protein kinase (p-AMPK) in skeletal muscle and liver, and of decreased expressions of fatty acid synthase (FAS) and peroxisome proliferator-activated receptor γ (PPARγ) in liver demonstrated that the dehydroeburicoic acid (TT) has anti-type 2 diabetic and anti-dyslipidemic applications in medical settings. |
| priorityDate | 2016-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.